KMDA logo

Kamada Ltd. (KMDA)

$8.16

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on KMDA

Market cap

$470916089

EPS

0.35

P/E ratio

--

Price to sales

2.58

Dividend yield

6.863%

Beta

0.8906

Price on KMDA

Previous close

$8.11

Today's open

$8.11

Day's range

$8.05 - $8.22

52 week range

$6.60 - $9.35

Profile about KMDA

CEO

Amir London

Employees

462

Headquarters

Rehovot,

Exchange

Nasdaq Global Select

Shares outstanding

57710305

Issue type

Common Stock

KMDA industries and sectors

Healthcare

Pharmaceuticals

News on KMDA

Kamada: Strong Growth, Improving Margins, Attractive Valuation, Upgrading To Buy

Kamada is upgraded to Buy, driven by strong KEDRAB demand, margin expansion, and raised 2026 guidance. KEDRAB maintains at least 50% U.S. market share, with robust demand expected to persist into 2027 and beyond. Distribution and biosimilars are rapidly expanding, targeting $20–$25 million revenue by 2030, diversifying KMDA's growth profile.

news source

Seeking Alpha • Nov 13, 2026

news preview

Kamada Q3 Earnings Call Highlights

Kamada NASDAQ: KMDA raised its 2026 revenue and adjusted EBITDA guidance after reporting double-digit third-quarter growth, as demand increased for its KEDRAB rabies treatment and other products.

news source

MarketBeat • Nov 9, 2026

news preview

Kamada Ltd. (KMDA) Q3 2026 Earnings Call Transcript

Kamada Ltd. (KMDA) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 9, 2026

news preview

Kamada Declares Cash Dividend of $0.14 Per Share; The Company Continues its Record-High Year

REHOVOT, Israel and HOBOKEN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.

news source

GlobeNewsWire • Nov 9, 2026

news preview

Kamada Reports Record-High First Nine Months 2026 Financial Results; Increases 2026 Annual Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2027

REHOVOT, Israel, and HOBOKEN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced financial results for the three months and nine months ended September 30, 2026, an increase of its 2026 annual guidance, and a dividend payment.

news source

GlobeNewsWire • Nov 9, 2026

news preview

Kamada (KMDA) Surpasses Q3 Earnings Estimates

Kamada (KMDA) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.09 per share a year ago.

news source

Zacks Investment Research • Nov 9, 2026

news preview

Kamada (KMDA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Kamada (KMDA) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

news source

Zacks Investment Research • Nov 9, 2026

news preview

Ahead of Kamada (KMDA) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Evaluate the expected performance of Kamada (KMDA) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026

REHOVOT, Israel and HOBOKEN, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.

news source

GlobeNewsWire • Nov 2, 2026

news preview

Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026

REHOVOT, Israel and HOBOKEN, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.

news source

GlobeNewsWire • Oct 19, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Kamada Ltd.

Open an M1 investment account to buy and sell Kamada Ltd. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in KMDA on M1